Niederman M S
State University of New York at Stony Brook School of Medicine.
Clin Chest Med. 1987 Sep;8(3):543-56.
Pneumonia remains a major source of morbidity and economic cost to our society, despite the availability of new antibiotics for therapy. To truly reduce the impact of this illness, serious efforts at preventing infection must be undertaken. In the area of community-acquired infections, safe and effective vaccines are available against S. pneumoniae, the most common pneumonic pathogen, and influenza. High-risk individuals (Table 2), who should be considered for vaccination, include: the elderly; residents of chronic-care facilities; and patients with chronic cardiac, respiratory, renal, and hematologic illnesses. Influenza vaccine is effective in preventing infections in such high-risk populations, including the elderly. There is some controversy about the efficacy of pneumococcal vaccine in an at-risk population with severe co-morbid illness, but there is little doubt that the vaccine is effective in a more healthy elderly population. Both patients and physicians fail to appreciate the safety and utility of these vaccines as evidenced by their low rates of use. Remarkably, only about 10 per cent of appropriate persons have ever received the pneumococcal vaccine, even though it needs to be given only once in a lifetime. In the area of nosocomial pneumonia, several strategies for prevention have proven to be useful. Most promising is the use of topical antibiotics in the upper and lower airway. Although the efficacy of this approach is well established, its safety has been questioned in prior studies. For many reasons, this position should be reevaluated, and this therapy should be considered for use in carefully selected patients at risk, using modern techniques of aerosol therapy. Active investigation into vaccines against gram-negative bacterial look to yield promising results in the future. In addition, passive "serum" therapy with preformed antibodies is a strategy for preventing gram-negative lung infection that has shown use in animal studies and may circumvent certain logistical problems of vaccine therapy. Infection control methods and sensible handling of respiratory therapy equipment are simple, yet effective, means for preventing contamination of the airway in mechanically ventilated patients. Finally, for patients both in and out of the hospital, an understanding of the nature of host defense impairments leading to pneumonia will allow for strategies to boost host defenses.(ABSTRACT TRUNCATED AT 400 WORDS)
尽管有新型抗生素可用于治疗,但肺炎仍然是我们社会发病和经济成本的主要来源。为了真正降低这种疾病的影响,必须认真努力预防感染。在社区获得性感染领域,有安全有效的疫苗可预防肺炎最常见的病原体肺炎链球菌和流感。应考虑接种疫苗的高危人群(表2)包括:老年人;长期护理机构的居民;以及患有慢性心脏、呼吸、肾脏和血液疾病的患者。流感疫苗在预防此类高危人群(包括老年人)的感染方面有效。对于肺炎球菌疫苗在患有严重合并症的高危人群中的疗效存在一些争议,但毫无疑问,该疫苗在更健康的老年人群中是有效的。患者和医生都没有认识到这些疫苗的安全性和实用性,其使用率较低就证明了这一点。值得注意的是,只有约10%的合适人群接种过肺炎球菌疫苗,尽管该疫苗一生只需接种一次。在医院获得性肺炎领域,已证明几种预防策略是有用的。最有前景的是在上、下呼吸道使用局部抗生素。尽管这种方法的疗效已得到充分证实,但其安全性在以前的研究中受到质疑。出于多种原因,这一观点应重新评估,并且应考虑使用现代雾化治疗技术,在经过精心挑选的高危患者中使用这种疗法。针对革兰氏阴性菌的疫苗的积极研究有望在未来取得有希望的结果。此外,用预先形成的抗体进行被动“血清”治疗是预防革兰氏阴性菌肺部感染一项策略,已在动物研究中显示出效果,并且可能规避疫苗治疗的某些后勤问题。感染控制方法以及合理处理呼吸治疗设备是预防机械通气患者气道污染的简单而有效的手段。最后,对于住院和出院的患者,了解导致肺炎的宿主防御受损的性质将有助于制定增强宿主防御的策略。(摘要截选至400字)